Skip to main content
ARMP logo

Armata Pharmaceuticals, Inc.

ARMPNYSEAMERICANHealthcareBiotechnology

$3.37Today:- (-)1Y −9.12%

As of Oct 16, 2026 close

Market cap
$191.71M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$2.75$16.34
Volume (live)
-
Avg. volume (3M)
288.28K

Armata Pharmaceuticals (ARMP) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Armata Pharmaceuticals used $25.76M of cash in operating activities and spent $542.00K on capital expenditures. That left free cash flow of −$26.30M. It repurchased $46.00K of its own shares.

Armata Pharmaceuticals Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Armata Pharmaceuticals, Inc. (ARMP) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
Operating Activities
Net Income-173.80-18.92-69.05-36.92-23.16-22.18-19.48-12.11-12.84
Depreciation & Amortization1.531.330.970.891.171.111.350.390.37
Deferred Income Tax0.000.000.000.000.000.00-0.45-0.33-1.30
Stock Based Compensation2.612.890.943.112.883.484.270.480.70
Change in Working Capital-1.41-2.10-9.650.44-3.22-0.87-2.190.35-0.46
Change in Accounts Receivable0.000.000.001.05-2.43-0.470.000.000.38
Change in Accounts Payable-0.33-3.760.043.670.180.54-1.370.34-0.84
Change in Other Working Capital139.90-18.59-8.63-4.02-3.88-0.95-0.820.000.38
Other Operating Activities139.90-18.5929.360.00-1.250.200.921.844.33
Net Cash from Operating Activities-25.76-37.55-47.42-32.48-23.58-18.27-15.58-9.38-9.19
Investing Activities
Capital Expenditures-0.54-1.88-8.14-2.21-1.30-0.82-0.13-0.04-0.06
Acquisitions0.000.000.000.000.000.003.010.070.00
Purchases of Investments0.000.000.000.000.000.000.00-3.390.00
Sales/Maturities of Investments0.000.000.000.000.000.000.0013.020.00
Other Investing Activities0.000.000.010.000.000.000.009.69-1.91
Net Cash from Investing Activities-0.54-1.88-8.13-2.21-1.30-0.822.88-0.04-0.06
Financing Activities
Debt Repayment25.0034.8954.030.000.000.720.000.00-0.82
Common Stock Issued0.660.130.0144.3926.9322.899.9812.259.35
Common Stock Repurchased-0.05-0.06-0.040.000.000.000.000.000.00
Other Financing Activities-0.05-0.06-0.04-0.50-1.41-0.40-1.000.200.13
Net Cash from Financing Activities25.6134.9653.9944.0225.5223.218.9812.458.67
Summary
Effect of Forex Changes on Cash0.000.000.00-4.760.000.000.000.000.00
Net Change in Cash-0.69-4.47-1.579.320.644.12-3.733.03-0.58
Cash at Beginning of Period14.7719.2420.8111.4910.856.7310.465.135.71
Cash at End of Period14.0814.7719.2420.8111.4910.856.738.165.13
Free Cash Flow-26.31-39.43-55.57-34.69-24.88-19.09-15.71-9.43-9.25

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Armata Pharmaceuticals Cash Flow

What is Armata Pharmaceuticals's free cash flow?

Armata Pharmaceuticals had negative free cash flow of $26.30M in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of −$25.76M minus $542.00K of capital expenditures.

How much does Armata Pharmaceuticals spend on capital expenditures?

Armata Pharmaceuticals spent $542.00K on capital expenditures in fiscal 2025, compared with $1.88M a year earlier.

Does Armata Pharmaceuticals pay dividends or buy back shares?

Yes. In fiscal 2025 Armata Pharmaceuticals returned $46.00K in share buybacks to shareholders, according to its cash flow statement.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition